A 37-year-old woman with confirmed COVID-19 pneumonia presented with erythematous lesions in the target distributed on the dorsal and ventral sides of the hands and elbows.
He also had painful ulcers on his lips, tongue and palate.
Ocular and genital mucosa were normal.
The lesions appeared on day 5 of treatment for COVID-19, which consisted of hydroxychloroquine (day 1: 2x400, days 2-4: 2x200 mg), and 1x500 mg consisting of 5x400 mg (1x400 mg)
Symptoms associated with COVID-19 pneumonia appeared 10 days before the rash.
The patient had no history of similar rashes.
She had no history of herpetic infection.
Complete blood count, biochemical parameters, and serological tests for IgM and IgG of herpes simplex virus, IgM and Epicostein IgG - IgM were within normal limits of cytomegalovirus and IgM and IgM and IgG and viral of CMV.
Biopsy was not performed due to the risk of infection.
The patient was diagnosed with severe polymorphous erythema and the medication was discontinued.
Treatment was initiated with 40 mg/day of oral methylprednisolone, with a decrease of 5 mg per day.
Antiseptic and topical anesthetic mouthwashes were also applied.
On day 8 of treatment, pneumonia and skin lesions disappeared considerably and the patient was discharged without further complications.
